News NICE backs use of post-stroke genetic testing NICE has launched a new consultation on the use of CYP2C19 genotype testing to guide treatment after a stroke or transient ischaemic attack (TIA) or ‘mini-stroke’.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face